MedTrace Logo

Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG

NCT04392739 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2024-09-19

Study results available
· View outcomes & findings →

Summary

Safety and PK study in adults weighing more than 120 kg

Conditions

Interventions

DRUG

Tpoxx

oral antiviral

Sponsors & Collaborators

Principal Investigators

  • Dennis Hruby, PhD · SIGA Chief Scientific Officer

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-07-19
Primary Completion
2019-12-05
Completion
2019-12-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04392739 on ClinicalTrials.gov